New stock news | Lanza Cheng once again submitted documents to the Hong Kong Stock Exchange, dedicated to the discovery, development, and commercialization of radiotherapy drugs for cancer diagnosis and treatment.

According to the Zhitong Finance APP, the Hong Kong Stock Exchange disclosed on June 12th that Yantai Lannacheng Biological Technology Co., Ltd. (hereinafter referred to as "Lannacheng") submitted an application to the Hong Kong Stock Exchange main board, with CICC as its exclusive sponsor. The company had previously submitted an application for listing to the Hong Kong Stock Exchange on September 29, 2025.